Abstract: SA-PO0851
Nefecon Treatment in Patients with IgAN: A Real-World Observational Study
Session Information
- Glomerular Management: Real-World Lessons and Emerging Therapies
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Gu, Chenjie, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
- Zhou, Jingying, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
- Kang, Le, Dalian University, Dalian, Liaoning, China
- Fang, Ming, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
Background
IgA nephropathy (IgAN) is a leading cause of primary glomerulonephritis worldwide. IgAN patients have higher risk of kidney failure and poor prognosis. Nefecon, a new oral targeted-release formulation of budesonide which acts on gut mucosal immune system, has been proven in reducing proteinuria and slowing down kidney function lost in patients with IgAN. Here, we report effectiveness and safety of Nefecon in IgAN clinical practice.
Methods
Biopsy-confirmed primary IgAN patients with Nefecon therapy were enrolled at the First Affiliated Hospital of Dalian Medical University. All patients had received optimized supportive therapy at least 3 months prior to Nefecon treatment. Urine protein-creatinine ratio (UPCR), estimated glomerular filtration rate (eGFR, 2021 CKD-EPI equation) were collected at baseline, 1 month, 3 months, and 6 months.
Results
Sixteen patients (12 females/4 males, 45±9 years old) who completed at least 6-month therapy with Nefecon were enrolled. At baseline, UPCR was 2168.65 (369.19, 2968.11) mg/g, eGFR was 43.24 (32.63, 53.85) mL/min/1.73 m2. During follow-up, the proportion of patients with >30% reduction in UPCR was 43.75% at month 1, 43.75% at month 3, and 68.75% at month 6. The mean percentage of eGFR increase was 1.87% at month 1, 2.86% at month 3, and 7.52% at month 6. Five patients(31%) developed facial edema during follow-up.
Conclusion
After 6 months, Nefecon has demonstrated promising preservation of kidney function aligning with significant proteinuria reduction, with a rather safe profile in IgAN patients.